Here are six points:
1. The company’s shares increased by .71 percent over the last four weeks.
2. NuVasive outperformed the S&P 500 by 3.54 percent in the past week.
3. Brokerage firm analysts agreed on the mean estimate for the short term price target as $58.25.
4. NuVasive’s company shares have increased 9.71 percent from its one-year high price.
5. The company’s shares dropped 4.58 percent in the last three months.
6. The year-to-date stock performance is 8.35 percent.
More articles on devices:
5 key notes on Medtronic’s new manufacturing facility
13 spine devices receive FDA 510(k) clearances in November
Medtronic and Samsung form alliance — 6 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
